Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: A controlled laboratory study

Psychopharmacology

Volumn 212, Issue 4, 2010, Pages 675-686

  Bedi, Gillinder ^a,b   Foltin, Richard W ^a,b   Gunderson, Erik W ^a,b   Rabkin, Judith ^a,b   Hart, Carl L ^a,b   Comer, Sandra D ^a,b   Vosburg, Suzanne K ^a,b   Haney, Margaret ^a,b  

^a Surgeons of Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Anorexia; Appetite stimulation; Dronabinol; HIV; THC

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; AZITHROMYCIN; DIDANOSINE; DRONABINOL; EFAVIRENZ; EMTRICITABINE; GEMFIBROZIL; LAMIVUDINE; LOPERAMIDE; LOPINAVIR; NEVIRAPINE; PLACEBO; RITONAVIR; SULFAMETHOXAZOLE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANOREXIA; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CANNABIS SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FOOD INTAKE; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MALE; MOOD; PRIORITY JOURNAL; REPEATED DRUG DOSE; SELF REPORT; SLEEP;

ADULT; AFFECT; ANOREXIA; APPETITE STIMULANTS; BODY WEIGHT; COGNITION; DOUBLE-BLIND METHOD; DRUG TOLERANCE; EATING; ENERGY INTAKE; FEEDING BEHAVIOR; HIV INFECTIONS; HUMANS; MALE; MARIJUANA SMOKING; NEW YORK CITY; PLACEBO EFFECT; SLEEP; SOCIAL BEHAVIOR; TETRAHYDROCANNABINOL; TIME FACTORS; TREATMENT OUTCOME;

EID: 78651301281     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1995-4     Document Type: Article

References (45)

1. Abrams DI (1998) Medical marijuana: Trials and tribulations. J Psychoactive Drugs 30:163-169
2. Abrams DI (2000) Potential interventions for HIV/AIDS wasting: An overview. JAIDS 25:S74-S80
3. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003) Short-term effects of cannabinoids in patients with HIV-1 infection. Ann Intern Med 139:258-266
4. American Psychiatric Association (1994) DSM-IV: Diagnostic and statistical manual of mental disorders. American Psychiatric Association
5. Ashton CH (2001) Pharmacology and effects of cannabis: A brief review. Br J Psychiatry 178:101-106
6. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV (1995) Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89-97
7. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7-14
8. Chubineh S, McGowan J (2008) Nausea and vomiting in HIV: A symptom review. Int J STD AIDS 19:723-728
9. Dansak DA (1997) Medical use of recreational drugs by AIDS patients. J Addict Dis 16:25-30
10. Davidson ES, Schenk S (1994) Variability in subjective responses to marijuana: Initial experiences of college students. Addict Behav 19:531-538
11. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J (2008) Blunted psychotomimetic and amnestic effects of delta-9-tetracannabinol in frequent users of cannabis. Neuropsychopharmacology 33:2505-2516
12. Evans SM, Foltin RW, Fischman MW (1999) Food "cravings" and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 32:331-349
13. Folstein MF, Luria R (1973) Reliability, validity, and clinical application of the visual analogue mood scale. Psychol Med 3:479-486
14. Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R (2004) Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDs 18:215-228
15. Grinspoon L, Bakalar JB (1997) Marihuana: The forbidden medicine. Yale University Press, New Haven
16. Hall W, Degenhardt L (2003) Medical marijuana initiatives. Are they justified? How successful are they likely to be? CNS Drugs 17:689-697
17. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385-394 (Pubitemid 29190007)
18. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395-404 (Pubitemid 29190008)
19. Haney M, Bisaga A, Foltin RW (2003) Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 166:77-85
20. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW (2004) Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology 29:158-170
21. Haney M, Rabkin J, Gunderson EW, Foltin RW (2005) Dronabinol and marijuana in HIV + marijuana smokers: Acute effects on caloric intake and mood. Psychopharmacology 181:170-178
22. Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW (2007) Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood and sleep. JAIDS 45:545-554
23. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW (2008) Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 197:157-168
24. Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW (2002a) Effects of oral THC maintenance on smoked marijuana selfadministration. Drug Alcohol Depend 67:301-309
25. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW (2002b) Comparison of smoked marijuana and oral ?9-tetrahydrocannabinol in humans. Psychopharmacology 164:407-415 (Pubitemid 35435717)
26. Hazekamp A, Ruhaak R, Zuurman L, Van Gerven J, Verpoorte R (2006) Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 95:1308-1317
27. Hollister LE (2000) An approach to the medical marijuana controversy. Drug Alcohol Depend 58:3-7
28. Hunt CA, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215:35-44
29. Institute of Medicine (1999) Marijuana and medicine: Assessing the science base. Institute of Medicine, Washington DC
30. Johanson C, Uhlenhuth E (1980) Drug preference and mood in humans: Diazepam. Psychopharmacology 71:269-273 (Pubitemid 11194003)
31. Johnson M, Charlebois E, Morin SF, Catz SL, Goldstein RB, Remien RH, Rotheram-Borus MJ, Mickalian JD, Kittel L, Samimy-Muzaffar F, Lightfoot MA, Gore-Felton C, Chesney A, Team NHLP (2005) Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage 29:193-205
32. Kirk JM, de Wit H (1999) Responses to oral tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav 63:137-142
33. Martin BR (2002) Medical marijuana: Moving beyond the smoke. Lancet 360:4-5
34. Mehra R, Moore BA, KC TJ, Fiellin DA (2006) The association between marijuana smoking and lung cancer: A systematic review. Arch Int Med 166:1359-1367
35. Parrott AC, Garnham NJ, Wesnes K, Pincock C (1996) Cigarette smoking and abstinence: Comparative effects upon cognitive task performance and mood state over 24 hours. Hum Psychopharmacol Clin Exp 11:391-400
36. Prentiss D, Power R, Balmas G, Tzuang G, Israelski D (2004) Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. JAIDS 35:38-45
37. Ramaekers JG, Kauert G, Theunissen E, Toennes S, Moeller M (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 23:266-277
38. Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde SV, Brockmoller J (2009) Interindividual variation in the pharmacokinetics of Delta-9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 85:273-276
39. Sheskin DJ (2000) Handbook of parametric and nonparametric statistical procedures, 2nd edn. CRC Press LLC, Boca Raton
40. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG (1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827-831
41. Taylor D, Poulton R, Moffitt TE, Ramankutty P, Sears MR (2000) The respiratory effects of cannabis dependence in young adults. Addiction 95:1669-1677
42. Taylor DR, Fergusson DM, Milne BJ, Horwood LJ, Moffitt TE, Sears MR, Poulton R (2002) A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction 97:1055-1061
43. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL (2000) Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31:803-805
44. Ware M, Rueda S, Singer J, Kilby D (2003) Cannabis use by persons living with HIV/AIDS: Patterns and prevalence of use. J Cannabis Ther 3:3-15
45. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A (2005) Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 29:358-367